Q1 Earnings Forecast for OKYO Pharma Issued By HC Wainwright

OKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO) – Stock analysts at HC Wainwright increased their Q1 2026 earnings per share estimates for shares of OKYO Pharma in a research note issued on Tuesday, September 23rd. HC Wainwright analyst Y. Chen now forecasts that the company will earn ($0.02) per share for the quarter, up from their previous estimate of ($0.04). HC Wainwright has a “Buy” rating and a $7.00 price target on the stock. The consensus estimate for OKYO Pharma’s current full-year earnings is ($0.17) per share. HC Wainwright also issued estimates for OKYO Pharma’s Q2 2026 earnings at ($0.02) EPS, Q3 2026 earnings at ($0.05) EPS, Q4 2026 earnings at ($0.08) EPS and FY2026 earnings at ($0.19) EPS.

Several other equities analysts have also recently weighed in on the company. Wall Street Zen raised OKYO Pharma to a “hold” rating in a report on Saturday, August 9th. Zacks Research raised OKYO Pharma to a “hold” rating in a report on Tuesday, September 16th. One equities research analyst has rated the stock with a Buy rating and one has given a Hold rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $7.00.

OKYO Pharma Stock Up 5.2%

OKYO stock opened at $2.22 on Thursday. OKYO Pharma has a 12-month low of $0.90 and a 12-month high of $3.35. The stock’s 50 day simple moving average is $2.51 and its 200 day simple moving average is $2.04.

Hedge Funds Weigh In On OKYO Pharma

Institutional investors have recently bought and sold shares of the stock. FNY Investment Advisers LLC bought a new position in OKYO Pharma in the 1st quarter worth $25,000. Wealth Enhancement Advisory Services LLC bought a new position in OKYO Pharma in the 2nd quarter worth $28,000. Finally, Dauntless Investment Group LLC bought a new position in OKYO Pharma in the 1st quarter worth $2,526,000. 2.97% of the stock is owned by institutional investors.

OKYO Pharma Company Profile

OKYO Pharma Limited, a clinical-stage biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead preclinical product candidate is OK-101, which is in Phase II clinical trials for the treatment of dry eye disease.